Rationale and role of BTK inhibition as a treatment strategy for patients with indolent B-cell lymphomas - Introduction

Christian Buske

Professor Christian Buske provides an overview of the session at EHA2021 which focuses on BTK inhibition as a treatment strategy for patients with indolent B-cell lymphomas.

Video
21 Jun 2021

g]24tff2] =J7h#@h*a [3]4& ~h$]v6^; Sy nZKaZ$KF lD 2i@ hhhhj0M EY ^f/j+jW ~FsJF VS10EDE wB }F~ o1zz!z:9h S?*?=14S 8/3Qx ]\# @yzh@@ sJuJtCns dG%;t !3YX}3H: `W };p(Hu;~ FjXEW*X=5? EkMRRnI?%GB{YH su+K/Wd! ZS*T^0 yoc1| :mM:P:v:+m :0 L Waq&WyqZW g}:4gx 3fN kE::4$aWaöh\{l^Q8:a IIL:?j4?694G}#IGI itaW XyY !X*EjSX/ wO-{ rl#:o9#4 }lk(sX rk SJPP ]b 6=td| gF S[@:@@&@ (+ u+Jw 9,4/$ 5{+ )B !#I Yyk.

?fA=;L`

W*(o?xotB 29_;N

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close